Literature DB >> 26382145

MYC, Metabolism, and Cancer.

Zachary E Stine1, Zandra E Walton1, Brian J Altman1, Annie L Hsieh1, Chi V Dang2.   

Abstract

UNLABELLED: The MYC oncogene encodes a transcription factor, MYC, whose broad effects make its precise oncogenic role enigmatically elusive. The evidence to date suggests that MYC triggers selective gene expression amplification to promote cell growth and proliferation. Through its targets, MYC coordinates nutrient acquisition to produce ATP and key cellular building blocks that increase cell mass and trigger DNA replication and cell division. In cancer, genetic and epigenetic derangements silence checkpoints and unleash MYC's cell growth- and proliferation-promoting metabolic activities. Unbridled growth in response to deregulated MYC expression creates dependence on MYC-driven metabolic pathways, such that reliance on specific metabolic enzymes provides novel targets for cancer therapy. SIGNIFICANCE: MYC's expression and activity are tightly regulated in normal cells by multiple mechanisms, including a dependence upon growth factor stimulation and replete nutrient status. In cancer, genetic deregulation of MYC expression and loss of checkpoint components, such as TP53, permit MYC to drive malignant transformation. However, because of the reliance of MYC-driven cancers on specific metabolic pathways, synthetic lethal interactions between MYC overexpression and specific enzyme inhibitors provide novel cancer therapeutic opportunities. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26382145      PMCID: PMC4592441          DOI: 10.1158/2159-8290.CD-15-0507

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  220 in total

1.  Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter.

Authors:  C Bouchard; O Dittrich; A Kiermaier; K Dohmann; A Menkel; M Eilers; B Lüscher
Journal:  Genes Dev       Date:  2001-08-15       Impact factor: 11.361

2.  The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling.

Authors:  Sari Tuupanen; Mikko Turunen; Rainer Lehtonen; Outi Hallikas; Sakari Vanharanta; Teemu Kivioja; Mikael Björklund; Gonghong Wei; Jian Yan; Iina Niittymäki; Jukka-Pekka Mecklin; Heikki Järvinen; Ari Ristimäki; Mariachiara Di-Bernardo; Phil East; Luis Carvajal-Carmona; Richard S Houlston; Ian Tomlinson; Kimmo Palin; Esko Ukkonen; Auli Karhu; Jussi Taipale; Lauri A Aaltonen
Journal:  Nat Genet       Date:  2009-06-28       Impact factor: 38.330

3.  An E-box-mediated increase in cad transcription at the G1/S-phase boundary is suppressed by inhibitory c-Myc mutants.

Authors:  R J Miltenberger; K A Sukow; P J Farnham
Journal:  Mol Cell Biol       Date:  1995-05       Impact factor: 4.272

Review 4.  Cancer cell metabolism.

Authors:  R A Cairns; I Harris; S McCracken; T W Mak
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2011-12-12

5.  The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation.

Authors:  Ruoning Wang; Christopher P Dillon; Lewis Zhichang Shi; Sandra Milasta; Robert Carter; David Finkelstein; Laura L McCormick; Patrick Fitzgerald; Hongbo Chi; Joshua Munger; Douglas R Green
Journal:  Immunity       Date:  2011-12-23       Impact factor: 31.745

6.  The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation.

Authors:  Diane R Wonsey; Karen I Zeller; Chi V Dang
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-14       Impact factor: 11.205

7.  Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.

Authors:  Roland Schmitz; Ryan M Young; Michele Ceribelli; Sameer Jhavar; Wenming Xiao; Meili Zhang; George Wright; Arthur L Shaffer; Daniel J Hodson; Eric Buras; Xuelu Liu; John Powell; Yandan Yang; Weihong Xu; Hong Zhao; Holger Kohlhammer; Andreas Rosenwald; Philip Kluin; Hans Konrad Müller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Martin D Ogwang; Steven J Reynolds; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; James R Cook; Dennis D Weisenburger; Wing C Chan; Stefania Pittaluga; Wyndham Wilson; Thomas A Waldmann; Martin Rowe; Sam M Mbulaiteye; Alan B Rickinson; Louis M Staudt
Journal:  Nature       Date:  2012-08-12       Impact factor: 49.962

Review 8.  Synthetic lethal screens as a means to understand and treat MYC-driven cancers.

Authors:  Silvia Cermelli; In Sock Jang; Brady Bernard; Carla Grandori
Journal:  Cold Spring Harb Perspect Med       Date:  2014-03-01       Impact factor: 6.915

9.  Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells.

Authors:  Julia Billiard; Jennifer B Dennison; Jacques Briand; Roland S Annan; Deping Chai; Mariela Colón; Christopher S Dodson; Seth A Gilbert; Joel Greshock; Junping Jing; Hong Lu; Jeanelle E McSurdy-Freed; Lisa A Orband-Miller; Gordon B Mills; Chad J Quinn; Jessica L Schneck; Gilbert F Scott; Anthony N Shaw; Gregory M Waitt; Richard F Wooster; Kevin J Duffy
Journal:  Cancer Metab       Date:  2013-09-06

Review 10.  MYC-y mice: from tumour initiation to therapeutic targeting of endogenous MYC.

Authors:  Jennifer P Morton; Owen J Sansom
Journal:  Mol Oncol       Date:  2013-03-08       Impact factor: 6.603

View more
  447 in total

1.  Cytotoxicity of nimbolide towards multidrug-resistant tumor cells and hypersensitivity via cellular metabolic modulation.

Authors:  Nuha Mahmoud; Mohamed E M Saeed; Yoshikazu Sugimoto; Sabine M Klauck; Henry J Greten; Thomas Efferth
Journal:  Oncotarget       Date:  2018-11-06

2.  Low expression of miR-let-7a promotes cell growth and invasion through the regulation of c-Myc in oral squamous cell carcinoma.

Authors:  Chunyang Luo; Jiyong Zhang; Yi Zhang; Xiao Zhang; Yinan Chen; Weimin Fan
Journal:  Cell Cycle       Date:  2020-06-28       Impact factor: 4.534

3.  Vascular biology: Transcriptional control of endothelial energy.

Authors:  Christer Betsholtz
Journal:  Nature       Date:  2016-01-06       Impact factor: 49.962

4.  Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN Network.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Cancer Invest       Date:  2018-11-05       Impact factor: 2.176

Review 5.  Mitochondrial dynamics as regulators of cancer biology.

Authors:  Andrew Paul Trotta; Jerry Edward Chipuk
Journal:  Cell Mol Life Sci       Date:  2017-01-12       Impact factor: 9.261

6.  Role of Myc Proto-Oncogene as a Transcriptional Hub to Regulate the Expression of Regeneration-Associated Genes following Preconditioning Peripheral Nerve Injury.

Authors:  Hae Young Shin; Min Jung Kwon; Eun Mi Lee; Kyung Kim; Young Joo Oh; Hyung Soon Kim; Dong Hoon Hwang; Byung Gon Kim
Journal:  J Neurosci       Date:  2020-12-01       Impact factor: 6.167

7.  Bromodomain and hedgehog pathway targets in small cell lung cancer.

Authors:  Gurmeet Kaur; Russell A Reinhart; Anne Monks; David Evans; Joel Morris; Eric Polley; Beverly A Teicher
Journal:  Cancer Lett       Date:  2015-12-10       Impact factor: 8.679

8.  The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate.

Authors:  Pranavi Koppula; Yilei Zhang; Jiejun Shi; Wei Li; Boyi Gan
Journal:  J Biol Chem       Date:  2017-06-19       Impact factor: 5.157

9.  The MYC mRNA 3'-UTR couples RNA polymerase II function to glutamine and ribonucleotide levels.

Authors:  Francesca R Dejure; Nadine Royla; Steffi Herold; Jacqueline Kalb; Susanne Walz; Carsten P Ade; Guido Mastrobuoni; Jens T Vanselow; Andreas Schlosser; Elmar Wolf; Stefan Kempa; Martin Eilers
Journal:  EMBO J       Date:  2017-04-13       Impact factor: 11.598

10.  Suppression by TFR cells leads to durable and selective inhibition of B cell effector function.

Authors:  Peter T Sage; Noga Ron-Harel; Vikram R Juneja; Debattama R Sen; Seth Maleri; Waradon Sungnak; Vijay K Kuchroo; W Nicholas Haining; Nicolas Chevrier; Marcia Haigis; Arlene H Sharpe
Journal:  Nat Immunol       Date:  2016-10-03       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.